Shares of McKesson Co. (NYSE:MCK) have been assigned an average recommendation of “Hold” from the twelve analysts that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $146.22.

MCK has been the topic of a number of research reports. ValuEngine lowered shares of Valero Energy from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. Guggenheim initiated coverage on shares of Adaptive Biotechnologies in a research report on Monday, July 22nd. They set a “buy” rating and a $47.00 price target on the stock. Zacks Investment Research lowered shares of Hersha Hospitality Trust from a “buy” rating to a “hold” rating in a research report on Thursday, May 2nd. Wolfe Research initiated coverage on shares of Iqvia in a research report on Tuesday, April 2nd. They set a “market perform” rating on the stock. Finally, Credit Suisse Group raised shares of StoneCo from a “neutral” rating to an “outperform” rating in a research report on Monday, July 22nd.

MCK traded up $0.98 during trading on Thursday, reaching $142.26. The company’s stock had a trading volume of 17,176 shares, compared to its average volume of 1,086,137. The company has a current ratio of 1.02, a quick ratio of 0.58 and a debt-to-equity ratio of 0.88. The stock has a fifty day simple moving average of $137.15. McKesson has a 1 year low of $106.11 and a 1 year high of $148.23. The company has a market capitalization of $25.90 billion, a P/E ratio of 10.48, a price-to-earnings-growth ratio of 1.42 and a beta of 1.11.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, May 8th. The company reported $3.69 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.66 by $0.03. McKesson had a net margin of 0.02% and a return on equity of 29.02%. The business had revenue of $52.43 billion for the quarter, compared to analyst estimates of $53.14 billion. During the same period last year, the company posted $3.49 EPS. The business’s revenue was up 1.6% on a year-over-year basis. On average, equities analysts expect that McKesson will post 14.17 earnings per share for the current fiscal year.

In other news, EVP Lori A. Schechter sold 2,766 shares of McKesson stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $133.59, for a total transaction of $369,509.94. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Britt J. Vitalone sold 832 shares of McKesson stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $129.17, for a total transaction of $107,469.44. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,174 shares of company stock worth $804,583. Corporate insiders own 0.88% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Gradient Investments LLC raised its position in McKesson by 1,944.4% in the second quarter. Gradient Investments LLC now owns 184 shares of the company’s stock valued at $25,000 after purchasing an additional 175 shares during the period. Mark Sheptoff Financial Planning LLC purchased a new stake in McKesson in the first quarter valued at approximately $27,000. Smart Portfolios LLC purchased a new stake in McKesson in the first quarter valued at approximately $35,000. Investors Research Corp purchased a new stake in McKesson in the first quarter valued at approximately $36,000. Finally, Berman Capital Advisors LLC raised its position in McKesson by 175.2% in the second quarter. Berman Capital Advisors LLC now owns 289 shares of the company’s stock valued at $37,000 after purchasing an additional 184 shares during the period. 88.92% of the stock is currently owned by institutional investors.

McKesson Company Profile

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.

Read More: Liquidity

Analyst Recommendations for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.